<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Raza A</submitter><funding>Center for Drug Design, University of Minnesota</funding><funding>NIH HHS</funding><pagination>1075</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9219802</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(6)</volume><pubmed_abstract>Supplementation of glutathione (GSH) levels through varying formulations or precursors has thus far appeared to be a tenable strategy to ameliorate disease-associated oxidative stress. Metabolic liability of GSH and its precursors, i.e., hydrolysis by the ubiquitous γ-glutamyl transpeptidase (γ-GT), has limited successful clinical translation due to poor bioavailability. We addressed this problem through the design of γ-GT-resistant GSH analogue, ψ-GSH, which successfully substituted in GSH-dependent enzymatic systems and also offered promise as a therapeutic for Alzheimer's disease (AD). With the aim to improve its bioavailability, we studied the utility of a ψ-GSH precursor, dipeptide &lt;b>2&lt;/b>, as a potential AD therapeutic. Compound &lt;b>2&lt;/b> retains the γ-GT stable ureide linkage and th</pubmed_abstract><journal>Antioxidants (Basel, Switzerland)</journal><pubmed_title>Dipeptide of ψ-GSH Inhibits Oxidative Stress and Neuroinflammation in an Alzheimer's Disease Mouse Model.</pubmed_title><pmcid>PMC9219802</pmcid><funding_grant_id>NA</funding_grant_id><funding_grant_id>R01AG062469</funding_grant_id><pubmed_authors>Xie W</pubmed_authors><pubmed_authors>More SS</pubmed_authors><pubmed_authors>Williams J</pubmed_authors><pubmed_authors>Raza A</pubmed_authors><pubmed_authors>Kim KH</pubmed_authors><pubmed_authors>Dronamraju VR</pubmed_authors><pubmed_authors>Vince R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dipeptide of ψ-GSH Inhibits Oxidative Stress and Neuroinflammation in an Alzheimer's Disease Mouse Model.</name><description>Supplementation of glutathione (GSH) levels through varying formulations or precursors has thus far appeared to be a tenable strategy to ameliorate disease-associated oxidative stress. Metabolic liability of GSH and its precursors, i.e., hydrolysis by the ubiquitous γ-glutamyl transpeptidase (γ-GT), has limited successful clinical translation due to poor bioavailability. We addressed this problem through the design of γ-GT-resistant GSH analogue, ψ-GSH, which successfully substituted in GSH-dependent enzymatic systems and also offered promise as a therapeutic for Alzheimer's disease (AD). With the aim to improve its bioavailability, we studied the utility of a ψ-GSH precursor, dipeptide &lt;b>2&lt;/b>, as a potential AD therapeutic. Compound &lt;b>2&lt;/b> retains the γ-GT stable ureide linkage and th</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-19T07:07:15.519Z</modification><creation>2025-02-19T03:22:37.235Z</creation></dates><accession>S-EPMC9219802</accession><cross_references><pubmed>35739972</pubmed><doi>10.3390/antiox11061075</doi></cross_references></HashMap>